Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs MasterCard Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while MasterCard Inc trades at $529 (market cap $465.42B). The key difference: MasterCard Inc is far larger — about 11.7× Alnylam Pharmaceuticals, Inc.'s market cap, and MasterCard Inc pays a 0.66% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | MA | |
|---|---|---|
Market Cap | $39.89B | $465.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $598.96 |
52-Week Low | $278.09 | $471.55 |
Enterprise Value | $38.15B | $476.16B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Mastercard (MA) trades at $526.74, up 0.68% today, with a bullish technical signal supported by moving averages and strong financial performance. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $4.75. Revenue grew to $32.79B in 2025, with a net income margin of 45.88%, while analyst consensus is strongly bullish with a $637.67 price target.
The outlook remains positive due to robust profitability and strategic AI initiatives, but risks include payment disruption from stablecoins and competitive pressures. Institutional buying activity underscores confidence, though high valuation multiples warrant monitoring for sustainability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
